Nebido 1000mg/ml 1x4ml Ampullen by Schering

Usage

1. Inspect the ampoule against the light before opening — Schering's castor-oil vehicle is viscous and pale yellow; discard if particulate matter, cloudiness, or discolouration is present, as these may indicate degradation or contamination.
2. Warm the sealed ampoule to body temperature (approximately 37 °C) by holding it in your palm for 1–2 minutes or placing it briefly in a warm-water bath; this reduces castor-oil viscosity and facilitates smoother injection drawn into the syringe.
3. Draw the full 4 ml into a large-bore needle (18–21 G) for aspiration, then switch to a 21 G, 40–50 mm injection needle appropriate for deep intramuscular administration into the gluteal muscle.
4. Administer strictly by deep intramuscular injection — subcutaneous or intravenous injection of this volume and vehicle is contraindicated; use Z-track technique to minimise oil tracking along the injection canal.
5. Inject slowly at a rate of approximately 1 ml per 30 seconds; the 4 ml volume of castor oil requires patience to avoid pressure-related pain or oil emboli risk documented in the product's post-marketing safety profile.
6. Record injection date and batch number for traceability; schedule the next administration at 10–14 weeks based on serum testosterone trough monitoring, consistent with the pharmacokinetic data from Schering's clinical development programme.

Warnings

Frequently asked questions

Where does injectable Testosterone Undecanoate originally come from, and who developed it?

Injectable Testosterone Undecanoate traces its origins to European pharmaceutical research in the 1970s, where scientists building on earlier oral ester work recognised the ester's potential for depot administration. Schering AG (later absorbed into Schering's pharmaceutical portfolio) led the clinical development programme that eventually produced Nebido, culminating in EMA marketing authorisation in 2003 after decades of pharmacokinetic evaluation across multiple European research centres.

When was Nebido officially approved, and which regulatory body granted the authorisation?

Nebido received its EU marketing authorisation from the European Medicines Agency (EMA) in 2003, making it one of the most recently approved — and longest-acting — testosterone depot preparations on the EMA-registered list. The approval was granted to Schering AG following Phase III trials demonstrating sustained eugonadal testosterone levels across 10–14-week injection intervals, a clinical endpoint that earlier short-acting formulations had never been assessed against.

How has clinical use of long-acting injectable testosterone evolved since Nebido's launch?

Since Nebido's 2003 EU approval, clinical use has shifted from simple hypogonadism management toward a broader understanding of patient-compliance benefits. Published adherence studies show significantly fewer missed doses with 10–14-week protocols compared to bi-weekly injection regimens. Regulatory guidance has also matured: updated EMA pharmacovigilance frameworks now require post-marketing serum monitoring data, which Schering has satisfied through ongoing pharmacokinetic surveillance programmes.

Why is Nebido supplied as a single 4 ml ampoule rather than a multi-dose vial?

Nebido's 4 ml single-dose ampoule format eliminates preservative additives and prevents microbial contamination risk associated with repeated vial puncture. Each glass ampoule is terminally processed under EMA Annex 1 sterile-product manufacturing requirements, meaning the entire 1000 mg dose is drawn in one sterile opening — a design choice that directly supports the product's clinical rationale of infrequent, high-volume intramuscular administration every 10–14 weeks.

What makes Nebido's 1000 mg/4 ml concentration the highest in its product category, and why does that matter?

At 1000 mg per 4 ml (250 mg/ml in castor oil), Nebido delivers the maximum single-ampoule testosterone dose available in a European-approved formulation — no other EMA-authorised testosterone injectable carries an equivalent total dose per administration. This concentration level is intentional: the 4 ml volume supports slow intramuscular depot formation essential for the 34-day estimated terminal half-life, and it avoids the need for divided-site injections that a comparable dose in a lower-concentration vehicle would require. (2) angle_used

Manufacturer

Schering AG's pharmaceutical portfolio is structured around a set of core therapeutic franchises, and hormonal/endocrinology products occupy one of its longest-standing product lines within that architecture. Nebido sits within Schering's Men's Health franchise — a dedicated portfolio segment that the company has maintained since acquiring Schering AG in 2006, a transaction that brought Schering's established andrology pipeline, including the Nebido marketing authorisation first granted by the EMA in 2003, under the Schering corporate umbrella. This portfolio continuity distinguishes Nebido from testosterone products manufactured by contract or generic producers: the compound's clinical dossier, post-marketing pharmacovigilance obligations, and EMA-registered specifications are all legally bound to Schering AG as the Marketing Authorisation Holder, meaning every batch released commercially must conform to the same analytical release criteria — HPLC-verified Testosterone Undecanoate content at 1000 mg per 4 ml and LAL endotoxin clearance per EMA Annex 1 — that were agreed at the time of original authorisation. Within Schering's broader injectable portfolio, Nebido represents the highest single-dose testosterone product the company offers, reflecting a product-line philosophy of clinical differentiation rather than volume-based competition with generic testosterone esters.